Clinical trial for solid tumors with novel small molecule agent

Rutgers Cancer Institute of New Jersey is offering a clinical trial examining the investigational treatment known as ONC201 in patients with solid tumors whose cancer no longer responds to standard therapy. Prior research on the study drug suggests that it may be capable of turning off proteins that maintain tumor growth and and may help kill cancer cells while sparing normal ones. (Mehr in: Cancer News — ScienceDaily)